QIAGEN (Suzhou) Closes $25 Million A Round for Precision Medicine

QIAGEN (Suzhou) Translational Medicine, a China precision medicine company, raised $25 million in a Series A funding led by Qiming Venture Partners. QIAGEN (Suzhou)  was founded in 2013 by QIAGEN, a global molecular diagnostics company headquartered in Germany, and BioBay, the Suzhou life science technology park. It specializes in developing biomarkers and stratifying patients in clinical trials. QIAGEN (Suzhou) said it plans to use the new capital to build a factory and expand its scientific team. More details.... Stock Symbol: (NSDQ: QGEN) Share this with colleagues: // //